Baraban Jay M, Tuday Eric, Berkowitz Dan E, Das Sam
Department of Neuroscience, School of Medicine, Johns Hopkins University, Baltimore, ML, United States.
Division of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, UT, United States.
Front Physiol. 2021 Sep 27;12:747789. doi: 10.3389/fphys.2021.747789. eCollection 2021.
Large artery stiffness (LAS) is a major, independent risk factor underlying cardiovascular disease that increases with aging. The emergence of microRNA signaling as a key regulator of vascular structure and function has stimulated interest in assessing its role in the pathophysiology of LAS. Identification of several microRNAs that display age-associated changes in expression in aorta has focused attention on defining their molecular targets and deciphering their role in age-associated arterial stiffening. Inactivation of the microRNA-degrading enzyme, translin/trax, which reverses the age-dependent decline in miR-181b, confers protection from aging-associated arterial stiffening, suggesting that inhibitors targeting this enzyme may have translational potential. As LAS poses a major public health challenge, we anticipate that future studies based on these advances will yield innovative strategies to combat aging-associated arterial stiffening.
大动脉僵硬度（LAS）是心血管疾病的一个主要独立危险因素，且会随着年龄增长而增加。微小RNA信号作为血管结构和功能的关键调节因子的出现，激发了人们对评估其在LAS病理生理学中作用的兴趣。几种在主动脉中表达呈现与年龄相关变化的微小RNA的鉴定，使人们将注意力集中在确定其分子靶点以及解读它们在与年龄相关的动脉僵硬度中的作用上。微小RNA降解酶转脂蛋白/转位蛋白（translin/trax）的失活可逆转miR-181b随年龄增长的下降，并赋予对衰老相关动脉僵硬度的保护作用，这表明靶向该酶的抑制剂可能具有转化潜力。由于LAS构成了一项重大的公共卫生挑战，我们预计基于这些进展的未来研究将产生对抗衰老相关动脉僵硬度的创新策略。
